company background image
HOOK logo

HOOKIPA Pharma NasdaqCM:HOOK Stock Report

Last Price

US$0.74

Market Cap

US$77.4m

7D

-9.2%

1Y

-28.5%

Updated

14 Jun, 2024

Data

Company Financials +

HOOKIPA Pharma Inc.

NasdaqCM:HOOK Stock Report

Market Cap: US$77.4m

HOOK Stock Overview

A clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

HOOK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

HOOKIPA Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HOOKIPA Pharma
Historical stock prices
Current Share PriceUS$0.74
52 Week HighUS$1.13
52 Week LowUS$0.41
Beta0.75
1 Month Change-13.45%
3 Month Change3.41%
1 Year Change-28.51%
3 Year Change-92.13%
5 Year Change-89.88%
Change since IPO-94.69%

Recent News & Updates

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Recent updates

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18
Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

Hookipa: Speculative Biotech With Key Catalysts In 2022

Mar 29

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Oct 01
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Checking Back In On HOOKIPA Pharma

Jun 22

Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers

Jun 08

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Apr 19
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

Mar 15
If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

Shareholder Returns

HOOKUS BiotechsUS Market
7D-9.2%0.02%1.2%
1Y-28.5%6.7%20.6%

Return vs Industry: HOOK underperformed the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: HOOK underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is HOOK's price volatile compared to industry and market?
HOOK volatility
HOOK Average Weekly Movement12.8%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: HOOK's share price has been volatile over the past 3 months.

Volatility Over Time: HOOK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011165Joern Aldagwww.hookipapharma.com

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.

HOOKIPA Pharma Inc. Fundamentals Summary

How do HOOKIPA Pharma's earnings and revenue compare to its market cap?
HOOK fundamental statistics
Market capUS$77.38m
Earnings (TTM)-US$47.52m
Revenue (TTM)US$53.55m

1.4x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HOOK income statement (TTM)
RevenueUS$53.55m
Cost of RevenueUS$84.31m
Gross Profit-US$30.76m
Other ExpensesUS$16.76m
Earnings-US$47.52m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin-57.44%
Net Profit Margin-88.73%
Debt/Equity Ratio1.1%

How did HOOK perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.